NHSGGC extra sample tissue resource to support PREDICT-Meso network
Research type
Research Tissue Bank
IRAS ID
289483
Contact name
Alexandrea MacPherson
Contact email
Research summary
NHSGGC biorepository extra sample tissue resource to support PREDICT-Meso (PRE-malignant Drivers Combined with Target-Drug validation in Mesothelioma) Network (PREDICT-Meso Research Tissue Bank)
REC name
West of Scotland REC 4
REC reference
21/WS/0011
Date of REC Opinion
16 Mar 2021
REC opinion
Further Information Favourable Opinion
Data collection arrangements
Tumour samples and other materials from patients are needed to develop new treatments for Mesothelioma. At present, these are stored in a large number of local pathology labs and in a few small tissue banks in multiple institutions. This makes effective use of this rare material difficult, slowing down progress in developing new Mesothelioma treatments. The PREDICT-Meso Research Tissue Bank will collate and store these valuable samples at one site and coordinate access for world-leading research teams. The tissues stored will include biopsies of benign pleural inflammation, paired with biopsies of mesothelioma that subsequently develops in the same patient. These ‘paired’ tissue biopsies will be supplemented by samples of blood, pleural fluid and exhaled breath, all associated with clinical information regarding each. The samples will be stored in the NHS Greater Glasgow & Clyde Biorepository, based on the Queen Elizabeth University Hospital campus in Glasgow. Patients will be able to provide written consent to their involvement by a variety of routes. Archived samples will also be retrieved and used for research where this is sufficient extra material for research purposes and current regulations allow, with the support of local pathology labs and the MesobanK team.
Research programme
The PREDICT-Meso Research Tissue Bank (RTB) is a key part of the PREDICT-Meso International Accelerator Network, funded by Cancer Research UK. The Network is made up of expert mesothelioma researchers from across the world and is arranged into 5 work packages. The aim of the Network is to understand how mesothelioma develops after decades of benign pleural inflammation and to design new effective therapies. A key requirement is collection of paired samples from patients with benign pleural inflammation that subsequently evolves into malignant pleural mesothelioma (MPM) during clinical follow-up. These samples will be compared using state-of-the-art laboratory techniques to understand the processes that drive Mesothelioma, and to build new models of disease and to test new treatments that emerge from the project. PREDICT-Meso will share samples and data widely, ensuring benefits for patients are realised as quickly as possible. The Network includes founding members in the UK, Spain, Italy and Belgium, and has an expanding number of new global partners. Our collaborators may be publicly, charitably or commercially funded, and applications will only be considered if the PREDICT-Meso RTB is satisfied that appropriate governance and regulatory standards are in place.
RTBTitle
NHSGGC biorepository extra sample tissue resource to support PREDICT-Meso (PRE-malignant Drivers Combined with Target-Drug validation in Mesothelioma) Network (PREDICT-Meso Research Tissue Bank)
Establishment organisation
NHSGGC Biorepository
Establishment organisation address
Level 3, Laboratory Medicine Building
Queen Elizabeth University Hospital, 1345 Govan Road
Glasgow
G51 4TY